Medimmune Limited

Cambridge Antibody Technology Limited

Lutz Jermutus

Ralph Raymond Minter

Melissa Marie Damschroder

Scott A Hammond

Sandrine Guillard

Ching Ching Leow

Carl Hay

Peter Pavlik

Robert E Hollingsworth

Phillip David Monk

Nicholas Durham

Celia Patricia Shorrock

Erin Sult

Kris Sachsenmeier

Jonathan Rios-Doria

Steve Rust

Li Cheng

Mary Antonysamy

James Geoghegan

Xiaojun Lu

Kim Rosenthal

Qihui Huang

Gundo Diedrich

Roland Bürli

Damian C Crowther

Maria Herva

Andrew Grier Buchanan

Albert George Thom

Maria Aleksandra Bednarek

Jonathan P Hatcher

Carl Innes Webster

Philip Ambery

Marcella Petrone

Andrew Buchanan

Philip David Monk

In some embodiments, the disclosure provides for a conjugate comprising: a) a peptide that competes with an Fc fragment of an IgG for binding to an Fc receptor; and b) a targeting moiety that targets molecular aggregates. In some embodiments, the disclosure provides for methods of using the conjugates for treating a disease or disorder associated with aggregate formation.

Conjugates for targeting and clearing aggregates

The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.

Binding molecules specific for CD73 and uses thereof

Provided herein are methods of preventing and treating obesity and diabetes in patients comprising administering GLP-1/glucagon agonists peptides.

Glucagon and GLP-1 co-agonists for the treatment of obesity

The disclosure provides transporter molecules capable of carrying agents of interest across the blood brain barrier. Also provided are polynucleotides encoding transporter molecules, methods making transporter molecules, and methods of using transporter molecules, e.g., for the diagnosis, prevention, or treatment of central nervous system diseases, disorders, or injuries.

Blood brain barrier transport molecules and uses thereof

Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralize IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.

Human antibody molecules for IL-13

Specific binding members, in particular human anti-IL-13 antibody molecules and especially those which neutralise IL-13 activity. Methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, including asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.

Methods of treatment using human antibody molecules for IL-13

A method of providing a subject polypeptide variant with improved stability compared with a parent subject polypeptide, employing translation and selection using an RNA expression system, wherein two or more stability selection pressures are applied simultaneously during translation, two or more stability selection pressures are applied simultaneously during selecting, or at least one stability selection pressure is applied during translation and continues to be applied during selecting, and at least one further stability selection pressure is applied during selecting.

Methods and means relating to protein variants

Growing community of inventors

Cambridge, United Kingdom

Lutz Jermutus